<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present a case of toxicity caused by a drug interaction between <z:chebi fb="0" ids="31348">capecitabine</z:chebi> and phenytoin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PHT</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The drug combination elevated the plasma level of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PHT</z:e> in a patient on chemotherapy with <z:chebi fb="0" ids="31348">capecitabine</z:chebi> for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Our patient was a 44-year-old woman diagnosed with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> in her 20's, being treated with <z:chebi fb="0" ids="39867">valproic acid</z:chebi> (VPA) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PHT</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Adjuvant chemotherapy with <z:chebi fb="0" ids="31348">capecitabine</z:chebi> began following surgery for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Seven weeks later, she developed numbness, dizziness, <z:hpo ids='HP_0001260'>dysarthria</z:hpo> and <z:hpo ids='HP_0002355'>difficulty walking</z:hpo>, and was hospitalized for investigation </plain></SENT>
<SENT sid="5" pm="."><plain>Her serum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PHT</z:e> level was elevated at 35 </plain></SENT>
<SENT sid="6" pm="."><plain>1 Î¼g/ mL </plain></SENT>
<SENT sid="7" pm="."><plain>This case suggests that when <z:chebi fb="0" ids="31348">capecitabine</z:chebi> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PHT</z:e> are coadministered, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PHT</z:e> levels should be monitored frequently, and that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PHT</z:e> dosage should be adjusted accordingly if it cannot be replaced by an alternative <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> </plain></SENT>
</text></document>